Trial Title:
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
NCT ID:
NCT06276309
Condition:
Neuroendocrine Neoplasm
China
Women
Cervical Cancer
Cervical Lesion
Conditions: Official terms:
Neuroendocrine Tumors
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Summary:
The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors
were collected, including age, preoperative biopsy pathology results, postoperative
histopathological results, TCT results, and colposcopy biopsy pathology results. At the
same time, paraffin tissue specimens (remaining specimens after pathological diagnosis)
from 100 cases of cervical neuroendocrine tumors from multiple centers across the country
were collected to establish a cervical neuroendocrine tumor data follow-up database.
Protein concentration and omics analysis were performed on the data results, to evaluate
the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins,
and to preliminarily explore its clinical application value.
Detailed description:
1. The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine
tumors were used for prognostic analysis.
(1) The diagnosis and treatment information of cervical neuroendocrine carcinoma in
multiple hospitals was collected, including clinical and medical data such as age,
preoperative HPV genotyping, preoperative biopsy pathological results, postoperative
histopathological results, FIGO staging, prognosis and survival information, and
follow-up of patients.
2. Protein and other omics analysis was performed on paraffin tissues of 100 cases of
cervical neuroendocrine tumors Paraffin samples collected from 100 cases of cervical
neuroendocrine tumors were identified, processed and segmtioned, and protein
concentration and proteome were determined to establish the molecular
characteristics and prognostic targets of cervical neuroendocrine tumors.
Criteria for eligibility:
Study pop:
All 300 patients were diagnosed with cervical neuroendocrine carcinoma by histopathology
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology
2. Clinical data were complete
Exclusion Criteria:
1. Patients who are not being treated in our hospital
2. Patients with lack of follow-up data, unable to obtain survival information
3. Patients call to refuse to participate in this project
4. The quality of paraffin specimens can not meet the requirements of proteome
concentration determination
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fujian Maternity and Child Health Hospital
Address:
City:
Fuzhou
Zip:
350001
Country:
China
Status:
Recruiting
Contact:
Last name:
Binhua Dong
Phone:
+8687558732
Email:
dbh18-jy@126.com
Facility:
Name:
Fujian Provincial Hospital
Address:
City:
Fuzhou
Country:
China
Status:
Recruiting
Contact:
Last name:
Dongjie Chen
Facility:
Name:
Ningde Mindong Hospital
Address:
City:
Ningde
Country:
China
Status:
Recruiting
Contact:
Last name:
Fang Xie
Facility:
Name:
Putian City first Hospital
Address:
City:
Putian
Country:
China
Status:
Recruiting
Contact:
Last name:
Yi Chen
Facility:
Name:
The Second Affiliated Hospital of Fujian Medical University
Address:
City:
Quanzhou
Country:
China
Status:
Recruiting
Contact:
Last name:
Luhong Li
Facility:
Name:
Zhangzhou affiliated Hospital of Fujian Medical University
Address:
City:
Zhangzhou
Zip:
363000
Country:
China
Status:
Recruiting
Contact:
Last name:
Feifeng Shi, M.D
Facility:
Name:
Maternal and Child Health Hospital of Hubei Province
Address:
City:
Wuhan
Country:
China
Status:
Recruiting
Contact:
Last name:
Hongning Cai, M.D
Phone:
+8615926224867
Facility:
Name:
Xiangya Hospital, Central South University
Address:
City:
Changsha
Country:
China
Status:
Recruiting
Contact:
Last name:
Yu Zhang
Facility:
Name:
Jiangxi maternal and Child Health Hospital
Address:
City:
Nanchang
Country:
China
Status:
Recruiting
Contact:
Last name:
Ling Li
Start date:
February 1, 2024
Completion date:
February 28, 2025
Lead sponsor:
Agency:
Fujian Maternity and Child Health Hospital
Agency class:
Other
Source:
Fujian Maternity and Child Health Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06276309
